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Background: Previous studies of atypical antipsychotic effects on cortical structures
in schizophrenia (SZ) and bipolar disorder (BD) have findings that vary between the
short and long term. In particular, there has not been a study exploring the effects of
atypical antipsychotics on age-related cortical structural changes in SZ and BD. This
study aimed to determine whether mid- to long-term atypical antipsychotic treatment
(mean duration = 20 months) is associated with cortical structural changes and whether
age-related cortical structural changes are affected by atypical antipsychotics.
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Methods: Structural magnetic resonance imaging images were obtained from 445
participants consisting of 88 medicated patients (67 with SZ, 21 with BD), 84
unmedicated patients (50 with SZ, 34 with BD), and 273 healthy controls (HC). Surfacebased analyses were employed to detect differences in thickness and area among
the three groups. We examined the age-related effects of atypical antipsychotics after
excluding the potential effects of illness duration.
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Results: Significant differences in cortical thickness were observed in the frontal,
temporal, parietal, and insular areas and the isthmus of the cingulate gyrus. The
medicated group showed greater cortical thinning in these regions than the unmediated
group and HC; furthermore, there were age-related differences in the effects of atypical
antipsychotics, and these effects did not relate to illness duration. Moreover, cortical
thinning was significantly correlated with lower symptom scores and Wisconsin Card
Sorting Test (WCST) deficits in patients. After false discovery rate correction, cortical
thinning in the right middle temporal gyrus in patients was significantly positively
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correlated with lower HAMD scores. The unmedicated group showed only greater
frontotemporal thickness than the HC group.
Conclusion: Mid- to long-term atypical antipsychotic use may adversely affect cortical
thickness over the course of treatment and ageing and may also result in worsening
cognitive function.
Keywords: schizophrenia, bipolar disorder, atypical antipsychotics, magnetic resonance imaging (MRI), cortical
thickness

Lesh et al., 2015; Gjerde et al., 2018; van Erp et al., 2018;
Di Sero et al., 2019; Liu et al., 2020). Similar results were
observed in BD patients (Gildengers et al., 2014; Birner et al.,
2020), although other studies failed to replicate the finding,
possibly due to differences in the duration (short, medium and
long-term) of atypical antipsychotic treatment and variability in
methodology and sample size (Hallahan et al., 2011; Hafeman
et al., 2012; Hibar et al., 2018). Longitudinal studies with 3, 7.2,
and 9 years of follow-up showed that atypical antipsychotics
were associated with progressive cortical structural loss (Ho
et al., 2011; Veijola et al., 2014; Akudjedu et al., 2020).
However, the findings were not replicated by a meta-regression
of longitudinal studies and a 5-year follow-up study (van
Haren et al., 2011; Vita et al., 2015). In these studies, a
higher mean daily intake or cumulative intake of atypical
antipsychotics was associated with less cortical structural loss.
Herein, we conduct a preliminary exploratory investigation of
the effects of mid- to long-term use of atypical antipsychotics on
cortical structures.
Few studies have focused on the effects of atypical
antipsychotic on age-related cortical structural changes.
Previous studies found greater age-related loss of cortical
structures in SZ and BD patients than in HC but were unable
to comprehensively examine the influence of antipsychotics
(Cropley et al., 2017; Abe et al., 2020). Most studies indicate the
absence of antipsychotic effects in the age-related trajectory of
cortical measures (Cropley et al., 2017; Altamura et al., 2018),
while some show the presence of antipsychotic effects (van Haren
et al., 2011). However, evidence regarding the effects of atypical
antipsychotics on age-related cortical structural changes in SZ
and BD remains uncertain.
Cortical volume is determined by both cortical thickness and
surface area, which have distinct genetic influences (Panizzon
et al., 2009) and different development trajectories (Wierenga
et al., 2014). Thus, we used SBM vertexwise analysis based
on cortical surface reconstruction to evaluate thickness and
surface area. We opted to combine SZ and BD patients for
the following reasons: The criteria for the current prevalent
classifications of SZ and BD were established mainly based
on clinical symptoms. However, SZ and BD share substantial
core features, as indicated by converging lines of evidence
from genetic, molecular, histological, and neuroimaging studies
(Garcia-Rizo et al., 2016; Goldsmith et al., 2016; Moser et al.,
2018; Akudjedu et al., 2020; Writing Committee for the
Attention-Deficit/Hyperactivity Disorder et al., 2020). Thus,
there appears to be a greater continuum between SZ and BD
than previously thought. Previous studies have also selected

INTRODUCTION
Schizophrenia (SZ) and bipolar disorder (BD) have substantial
overlap in genetic vulnerability (The International Schizophrenia
Consortium, Purcell et al., 2009; Network and Pathway
Analysis Subgroup of Psychiatric Genomics Consortium,
2015), brain structural abnormalities (Goodkind et al., 2015),
symptomatology, and cognitive deficits (Tamminga et al., 2013),
suggesting a common neurobiological mechanism underlying
the two psychiatric conditions. Atypical antipsychotics are
first-line treatment options for SZ and BD (Meltzer, 2013) and
are effective for treating psychotic symptoms in both disorders
(Leucht et al., 2009). They are the mainstay long-term treatment
for SZ. Atypical antipsychotics combined with mood stabilizers
constitute the mainstay of acute management of bipolar mania
and depression and the long-term management of BD (Grande
et al., 2016). However, the effects of atypical antipsychotics
on cortical structures, especially age-related effects, are still
unclear (Goff et al., 2017). Potential effects could have important
implications for the course and prognosis of illness.
Previous magnetic resonance imaging (MRI) studies of
antipsychotic effects have mainly focused on morphometric
changes in cortical volume, thickness and surface area. There
may be differences in the short- and longer-term (mid-to-longterm) effects of atypical antipsychotics treatment on cortical
structures, such as clinical trials examining the cortical structural
changes during short-term (less than 3 months) antipsychotic
treatment have reported that cortical thickness is maintained
or even increased after 6–12 weeks of antipsychotic treatment
(Goghari et al., 2013; Jessen et al., 2018; Nelson et al., 2020),
while longer-term (more than 3 months) studies have shown
cortical structural loss compared to healthy controls (HC)
(Lieberman et al., 2005; Ahmed et al., 2015; Guo et al., 2019;
Voineskos et al., 2020). In the largest randomized longitudinal
study to date comparing the effects of antipsychotic medication
types on brain volumes, olanzapine was found to reduce brain
volumes over a 1-year period (Lieberman et al., 2005). In the
most recent double-blind, randomized, placebo-controlled trial,
major depressive disorder (MDD) patients who were exposed
to olanzapine had a significant decrease in cortical thickness
across a 6-month period compared with those who took a placebo
(Voineskos et al., 2020). Due to the challenges of conducting
clinical trials to study atypical antipsychotic effects for more than
1 year, observations mostly come from cross-sectional studies and
longitudinal studies with naturalistic designs. For example, crosssectional studies of SZ patients undergoing current or chronic
(over 5 years) treatment suggest cortical loss (Haijma et al., 2013;
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criteria for SZ and BD and had no other comorbid Axis I
disorder. HC participants did not have current or lifetime
Axis I disorders or a history of psychotic, mood, or other
Axis I disorders in first-degree relatives, as determined by
detailed family history. HC were matched by age and gender
with the medicated and unmedicated patients. Participants
were excluded if any of the following were present: (1)
substance/alcohol abuse or dependence, (2) concomitant major
medical disorder, (3) history of electroconvulsive therapy
or transcranial magnetic stimulation therapy, (4) history of
head trauma with loss of consciousness for ≥5 min or any
neurological disorder and (5) any contraindications for magnetic
resonance imaging (MRI).
Symptom severity was assessed by the Hamilton Depression
Scale (HAMD), the Hamilton Anxiety Scale (HAMA), the
Young Mania Rating Scale (YMRS), and the Brief Psychiatric
Rating Scale (BPRS); cognitive function was evaluated by the
Wisconsin Card Sorting Test (WCST). Demographic and clinical
information are detailed in Table 1.

samples of SZ and BD patients to explore antipsychotic effects
(Cross-Disorder Group of the Psychiatric Genomics Consortium,
2013; Ansell et al., 2015; Goodkind et al., 2015). Thus, SZ
and BD patients were combined here. To our knowledge, only
two studies have investigated how atypical antipsychotics are
associated with cortical thickness in SZ and BD. One crosssectional study did not include an unmedicated comparison
group or clear determination of the duration of medication
use; it found that SZ and BD patients had thinner medial
frontal, parietal and fusiform areas and thicker precentral and
postcentral gyri compared to HC (Ansell et al., 2015). One
recent naturalistic longitudinal study of psychosis patients with
a 3-year follow-up period reported a significantly increased
rate of cortical thinning in the left lateral orbitofrontal region
compared with HC (Akudjedu et al., 2020). However, evidence
of the mid- to long-term effects of atypical antipsychotics
is still needed.
Herein, we aimed to determine whether mid- to longterm atypical antipsychotic treatment is associated with cortical
structural changes in a real-world observation and, if so, whether
age-related cortical structural changes are affected by atypical
antipsychotics. We compared cortical thickness and area in
SZ and BD patients who had been treated for more than
3 months with atypical antipsychotics, patients who received no
psychotropic medication, and HC. We also examined the effects
of atypical antipsychotics on clinical symptoms and cognitive
function. We hypothesized that regional cortical thickness
was more vulnerable to the effects of atypical antipsychotics
than surface area was. We also hypothesized that greater
cortical thinning would be found in medicated patients than in
unmedicated patients and HC and that atypical antipsychotics
would affect age-related changes.

Pharmacological Treatment
We reviewed information on the type, dosage, and duration of
medication recorded at the time of the MRI scan. The treatments
received reflected real-world clinical practice. According to the
existing literature on cortical structure changes following the
administration of antipsychotics (Lesh et al., 2015), a treatment
duration of more than 3 months would be sufficient to observe
brain changes associated with atypical antipsychotic use in our
samples. On the basis of existing literature on antipsychotic
washout (Garver et al., 2005), we considered subjects who were
medication naive or had not taken any psychotropic medication
in the 2 months prior to the MRI scanning unmedicated.
The mean duration of atypical antipsychotic treatment was
20 months; in 78% (69/88) of participants, the duration was
more than 6 months, and 61% (54/88) of the participants,
the duration was more than 1 year. In the medicated group,
65 patients took a single atypical antipsychotic, and the other
23 patients took 2 atypical antipsychotics simultaneously. No
patients were taking typical antipsychotics, but 15 patients were
taking antidepressants (escitalopram, fluoxetine, fluvoxamine,
and sertraline) at the time of scanning, and 17 patients
were taking anticonvulsants (magnesium valproate and sodium
valproate). Doses of antipsychotics were converted to olanzapine
equivalents (Leucht et al., 2016). In the unmedicated group,
68 patients were medication naive, and the remaining 16 had
discontinued psychotropic medication more than 2 months
before the study.

MATERIALS AND METHODS
Participants
The study included a total of 445 individuals aged 13–45 years:
88 medicated patients (67 with SZ, 21 with BD) who were
treated with atypical antipsychotics for at least 3 months, 84
unmedicated patients (50 with SZ, 34 with BD) who had received
no pharmacological treatment for at least 2 months or were
medication naive, and 273 HC. Patients were recruited from
the inpatient services of the Shenyang Mental Health Centre
and the outpatient services of the First Affiliated Hospital of
China Medical University. HC participants were recruited from
the local community. All participants provided written informed
consent after receiving a detailed description of the study. The
study was approved by the Institutional Review Board of China
Medical University.
All participants were independently assessed by two experttrained psychiatrists using the Structured Clinical Interview
for the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) Axis I Disorders (age ≥18 years)
or the Schedule for Affective Disorders and Schizophrenia for
School-Age Children-Present and Lifetime version (K-SADSPL) (age <18 years). All patients met the DSM-IV diagnostic
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MRI Acquisition
MRI scans were acquired on a GE signa HDX 3.0T scanner at
the First Affiliated Hospital of China Medical University with
a standard 8-channel head coil. A 3D fast-spoiled gradientecho sequence [3D-FSPGR: TR = 7.1 ms, TE = 3.2 ms,
matrix = 240 × 240, field of view (FOV) = 24 cm × 24 cm, voxel
size = 1 mm ∗ 1 mm ∗ 1 mm, slice thickness = 1.0 mm without
a gap, 176 slices in total, and scan time = 8 min 6 s] was used to
obtain sagittal T1-weighted structural images of the whole brain.
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TABLE 1 | Demographic, clinical characteristics and cognitive function of healthy controls, the medicated patients, and the unmedicated patients.
Variable

HC (n = 273)

Patients (n = 172)
Medicated patients (n = 88)

Unmedicated patients (n = 84)

F/χ2 /t-values

p-values

Demographic characteristic
26.59 (7.15)

25.47 (8.12)

25.11 (8.19)

1.609$

0.201

Male

107 (39%)

38 (43%)

34 (40%)

0.443$

0.801

Right handedness

253 (94%)

232 (90%)

75 (89%)

3.264$

0.515

Illness duration (months)

–

59.20 (59.65)

17.01 (28.52)

30.059%

<0.001

First episode, yes

–

39 (44%)

65 (77%)

18.851%

<0.001

(n = 251)

(n = 74)

(n = 65)

1.05 (1.71)

5.47 (6.05)

13.40 (9.43)

−5.827%

<0.001

(n = 250)

(n = 69)

(n = 60)

0.92 (2.11)

3.88 (4.02)

10.93 (9.00)

−5.602%

<0.001

(n = 245)

(n = 63)

(n = 60)

0.22 (0.83)

2.84 (6.81)

4.30 (8.84)

−1.028%

0.306

(n = 189)

(n = 78)

(n = 68)

18.41 (1.18)

28.33 (10.41)

34.51 (12.44)

−3.267%

0.001

Age (years)

Clinical characteristic

HAMD Total
HAMA total
YMRS total
BPRS total
Cognitive function
WCST

(n = 194)

(n = 53)

(n = 47)

Corrected responses

31.53 (11.54)

20.06 (11.36)

23.87 (12.64)

−1.590%

0.115

Categories completed

4.19 (2.09)

2.25 (2.24)

2.66 (2.09)

−0.954%

0.342

16.55 (11.69)

27.94 (11.36)

24.13 (12.64)

1.590%

0.115

Perseverative errors

5.98 (6.98)

10.83 (8.37)

9.68 (11.37)

0.580%

0.563

Non-perseverative errors

10.52 (6.54)

17.11 (7.70)

14.49 (8.34)

1.635%

0.105

Duration (months)

–

(n = 83) 20.47 (25.55)

–

Dose OPZ (mg)

–

(n = 64) 8.27 ± 6.49

–

Total errors

Medication
Antipsychotic use

Antipsychotic type
Amisulpride

–

3 (3%)

–

Aripiprazole

–

24 (27%)

–

Clozapine

–

12 (14%)

–

Olanzapine

–

17 (19%)

–

Paliperidone

–

2 (2%)

–

Quetiapine

–

17 (19%)

–

Risperidone

–

33 (38%)

–

Ziprasidone

–

3 (3%)

–

Antidepressants (%)

–

15 (17%)

–

Anticonvulsants (%)

–

17 (19%)

–

Data were presented as either n (%) or mean (SD). HC, Healthy Controls; HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale; YMRS, Young Manic
Rating Scale; BPRS, Brief Psychiatric Rating Scale; WCST, Wisconsin Card Sorting Test. OPZ, Olanzapine equivalent value. $ The examination among the medicated,
unmedicated, and HC groups. % The examination between the medicated and unmedicated groups.

Data Processing
Structural MRI images were processed by the Connectome
Computation System (CCS1 ) (Zuo et al., 2013), an integrated
informatic platform for multimodal neuroimaging data mining
and discovery sciences. Methodological details of the processing
have been provided in previous studies (Jiang et al., 2015).
Briefly, the CCS processing pipeline employed in the present
work included two major parts: (1) volBrain (Manjon and
Coupe, 2016) performs noise removal, intensity variation

correction, and extraction of brain tissues; (2) FreeSurfer (version
6.02 ) performs cortical surface reconstruction with a series of
functions, including brain tissue segmentation, mesh tessellation
and deformation to tissue boundaries, surface topological defect
correction, and surface inflation into a sphere. All outcomes
of the above preprocessing were visually inspected by two
researchers, and no participants needed manual editing. Cortical
thickness and surface area were calculated in native space.
Specifically, the thickness of each vertex was the mean value

1

2

https://github.com/zuoxinian/CCS
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To determine the age-related effects on cortical measurements
in the three groups, we used the mean values of the cortical
measurements in regions with group-level differences and
ran a GLM. The cortical measurements were considered
dependent variables. Fixed factors included age and group
(HC, unmedicated, medicated). Significant interaction effects
(age × group) were first examined among the three groups to
explore the regions showing age-related alterations and were
further disentangled using post hoc analysis between each pair of
groups to test for differential rates of age-related changes across
groups. Additionally, to determine the effects of illness duration
on our findings, we investigated the (illness duration × group)
interactions. The results were corrected using the FDR method,
with p < 0.05.

of twice the shortest calculated distance between the white
surface (white–gray interface) and the pial surface (greyCSF interface) and vice versa. Cortical thickness has been
demonstrated to show high test–retest reliability (Madan and
Kensinger, 2017). The cortical surface area was derived as the
total area of the triangles connected to a vertex. All individual
maps of cortical thickness and surface area were smoothed
of 10 mm full width at half-maximum (FWHM) using a
Gaussian filter and transferred to the standard spherical surface
(fsaverage).

Statistical Analysis
Statistical analyses of demographic and clinical characteristics
were performed using analysis of variance (ANOVA), two-sample
t-tests, or χ2 tests.
A general linear model (GLM) was applied to examine
the vertexwise differences in morphometry, including cortical
thickness and surface area, among the three groups for the
left and right hemispheres. Age and gender were modeled
as covariates of interest. We then tested the effects of the
group differences in the two morphometric measurements with
statistical correction for multiple comparisons based on the
Monte Carlo clusterwise simulation approach, with a p-threshold
of 0.001 at the vertex level and a p-threshold of 0.01 at the
cluster level (Hagler et al., 2006). We also performed vertexwise
post hoc t-tests for cortical thickness between each pair of
groups (medicated vs. HC, unmedicated vs. HC, medicated vs.
unmedicated). A three-group comparison of cortical thickness
that included intracranial volume (ICV), age and gender as
covariates were also performed (see Supplementary Material).
Vertexwise analyses of cortical thickness between the diagnostic
subgroups were also performed to test for effects of diagnosis:
BD/SZ (see Supplementary Material).
For each region showing group-level differences, the mean
values of the cortical measures were extracted. Post hoc
two-sample t-tests were applied to test the differences in
effects between each pair of groups in these regions. Multiple
comparisons were corrected using the false discovery rate (FDR)
method, and the significance level was set at p < 0.05. The
duration of illness was included as a covariate of no interest in
the patient subgroup comparison. Multiple regression analyses
were used to evaluate the relationships between cortical measures
in regions showing group-level differences with 5 potential
moderators [diagnosis: BD/SZ, age, gender, atypical antipsychotic
use (yes/no), and illness duration] in patients. The 5 moderators
were entered concurrently as independent effects, allowing us
to examine the magnitude of influence among them, especially
illness duration and antipsychotic use. The results were corrected
using the FDR method, with p < 0.05.
To determine potential relationships between the thickness or
surface area of regions showing significant group differences and
antipsychotic dosage and duration, symptom severities (HAMD,
HAMA, YMRS, and BPRS scores) and cognitive function (WCST
scores) in all patients (unmedicated and medicated), exploratory
partial correlation analysis controlling for age and gender was
performed. The results were corrected using the FDR method,
with p < 0.05.
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RESULTS
Demographic and Clinical Data
Demographic and clinical details are presented in Table 1. We
found no significant differences in age, gender or handedness
among the three groups. We did observe that the medicated
group had significantly lower mean HAMD, HAMA and BPRS
scores; longer illness duration; and lower first-episode rates
than the unmedicated group (p < 0.05). Demographic and
clinical details of the SZ and BD patients are shown in
Supplementary Table 1.

Group Differences in Cortical
Morphology
A three-group analysis of cortical thickness showed 13 regions
with significant group differences (Table 2 and Figure 1A).
Post hoc analysis showed that compared to the unmedicated
and HC groups, the medicated group demonstrated widespread
cortical thinning in the bilateral insula, the bilateral isthmus
of the cingulate cortex, the bilateral superior frontal gyrus,
and the bilateral superior temporal gyrus as well as in the
right precentral gyrus, left inferior temporal gyrus, right middle
temporal gyrus, right lateral orbitofrontal cortex and right
superior parietal gyrus compared with the unmedicated group
and HC. Compared to the HC group, the unmedicated patient
group showed increased cortical thickness in the left inferior
temporal gyrus and the left superior frontal gyrus (Figure 1B).
When illness duration was included as a covariate in comparisons
of patients (medicated vs. unmedicated), all significant regions
except the right parietal cortex survived. We did not detect
any significant differences in cortical surface area among the
three groups. The results of vertexwise post hoc t-tests of
cortical thickness were presented in Figure 2 and Supplementary
Tables 2, 3. Compared to the HC and unmedicated group, the
medicated group showed cortical thinning in multiple regions.
The unmedicated group showed no significant differences in
cortical thickness compared with HC. The results of three-group
analysis of cortical thickness controlling for ICV, age and gender
can be found in Supplementary Material, which were similar to
the above findings. The details of the effects of diagnosis: BD/SZ
on cortical thickness can be found in Supplementary Material.
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TABLE 2 | Cortical regions with significant difference in cortical thickness among healthy controls, the medicated patients, and the unmedicated patients.
Brain region

Cluster size (mm2 )

Talairach Coordinates (Peak Vertex)

p-values

Left hemisphere
Inferior temporal gyrus

546.49

−53.4

−19.2

−30.3

< 0.001

Insula

354.44

−33.7

14.9

13

< 0.001

Superior frontal gyrus

339.42

−6.8

37.9

46.6

< 0.001

Superior temporal gyrus

331.48

−47.6

4.8

−27.9

0.001

Isthmus cingulate gyrus

224.27

−12.3

−40.8

33.6

0.009

Right hemisphere
1090.79

54.4

3.4

−31.2

< 0.001

Insula

736.88

32.2

9.4

9.2

< 0.001

Lateral orbitofrontal cortex

480.16

33.3

31.3

−11.8

< 0.001

Precentral gyrus

387.28

24.1

−13.8

63.8

< 0.001

Isthmus cingulate gyrus

344.42

4.4

−42.2

29.9

< 0.001

Superior parietal cortex

321.1

25.1

−60.5

33

< 0.001

Superior frontal gyrus

268.73

12.7

19.8

37.4

0.003

Superior temporal gyrus

229.69

57.1

−12.5

−4.7

0.008

Middle temporal gyrus

inferior temporal gyrus, the right middle temporal gyrus, the
right lateral orbitofrontal cortex and the right superior parietal
gyrus. Regarding cognitive function, WCST deficits in patients
were significantly correlated with cortical thinning (correct
responses and completed categories were positively correlated
with cortical thickness; total errors, perseverative errors, and
non-perseverative errors were negatively correlated with cortical
thickness) in the right superior frontal gyrus, the left isthmus of
the cingulate cortex, the right middle temporal gyrus, the right
lateral orbitofrontal cortex and the left superior temporal gyrus.
All the results above were set at p < 0.05 uncorrected, and the p
and r values are listed in Table 3. After FDR correction, there was
still a significant positive correlation between cortical thickness in
the right middle temporal gyrus and the HAMD total (r = 0.283,
p = 0.026), somatic anxiety (r = 0.295, p = 0.030), and psychic
anxiety scores (r = 0.263, p = 0.041). The results of exploratory
partial correlation analyses controlling for age, gender and illness
duration can be found in Supplementary Table 5.

The results do not indicate diagnostic differences between BD and
SZ with regard to the relationship between atypical antipsychotic
treatment and cortical thickness alterations.
Multiple regression analyses in patients showed that diagnosis
(BD/SZ) did not have significant effects on cortical thinning in
all regions after FDR correction. Age had significant effects on
cortical thinning in all regions (−0.008 to −0.003 mm/year)
except the right middle temporal gyrus. Gender did not have
significant effects on cortical thinning in all regions. Atypical
antipsychotic use had significant effects on cortical thinning in
all regions (b = −0.177 to −0.060 mm/year). Illness duration
did not have significant effects on cortical thinning in all
regions (Supplementary Table 4). We also used these possible
confounding factors as covariates to observe the effect on
the results. Potential confounding factors [diagnosis: BD/SZ,
age, gender, duration of illness, antidepressants (yes/no) and
anticonvulsants (yes/no)] had little impact on the results
(Supplementary Figures 1–3). Additionally, higher olanzapine
dose equivalents were significantly correlated with cortical
thinning in the left superior temporal gyrus (r = −0.362,
p = 0.011) after FDR correction. There was no significant
correlation between duration of antipsychotic treatment and
cortical thickness.
Regarding clinical symptoms, the HAMD scores of patients
were significantly positively correlated with cortical thinning in
the left isthmus of the cingulate cortex and the right middle
temporal gyrus, right lateral orbitofrontal cortex, left superior
temporal gyrus and left inferior temporal gyrus. The HAMA
total score of patients was significantly positively correlated with
cortical thinning in the left isthmus of the cingulate cortex, the
right middle temporal gyrus and the left superior temporal gyrus.
The YMRS total score in patients was significantly negatively
correlated with cortical thinning in the left superior frontal
gyrus. BPRS scores were significantly positively correlated with
cortical thinning in the bilateral insula, the bilateral isthmus
of the cingulate cortex, the left superior frontal gyrus, the left
superior temporal gyrus, the right precentral gyrus, the left
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Age-Related Differences in Cortical
Morphology
Age-related effects on cortical thickness were observed in all 13
regions, showing group-level differences after FDR correction
(Figure 3). Post hoc analyses showed that medicated patients had
greater age-related cortical thinning in most (9 of 13) of these
regions than did the unmedicated patients and HC (Table 4).
When the same effects were examined in relation to illness
duration, no illness duration effects were found.

DISCUSSION
In this study, we found significant cortical thickness differences
in the frontal, temporal, parietal, cingulate gyrus isthmus and
insula areas among the three groups, with medicated patients
showing significant cortical thinning. No differences in cortical
surface area were found among the three groups. Furthermore,
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FIGURE 1 | Significant differences in cortical thickness among healthy controls, medicated patients, and unmedicated patients. (A) Regions with significant
thickness differences among the three groups. The significance level was set at p < 0.001 at the vertex level with Monte Carlo clusterwise simulation correction for
multiple comparisons (p < 0.01, corrected). The color bar represents the t-value. (B) Post hoc pairwise comparisons showing thickness differences between each
pairing (HC vs. medicated, HC vs. unmedicated, medicated vs. unmedicated). The significance level was set at p < 0.05, with FDR correction for multiple
comparisons. ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. HC, healthy controls; R, right; L, left; SPG; superior parietal gyrus; ICG, isthmus of the cingulate cyrus; mSFG,
medial superior frontal gyrus; PreCG, precentral gyrus; INS, insula; MTG, middle temporal gyrus; lOFC, lateral orbitofrontal cortex; STG, superior temporal gyrus;
ITG, inferior temporal gyrus.

there were age-related differences in the effects of atypical
antipsychotics in most (9 of 13) regions in the medicate group
compared to the unmedicated and HC groups.
These findings were not related to illness duration. In
an exploratory correlation analysis, cortical thinning in most
regions was significantly positively correlated with lower HAMD,
HAMA, and BPRS scores and WCST deficits (p < 0.05,
uncorrected). After FDR correction, cortical thinning in the right
middle temporal gyrus in patients was significantly positively
correlated with lower HAMD total, somatic anxiety, and psychic
anxiety scores. Finally, unmedicated patients had greater cortical
thickness than HC only in the frontotemporal region.
In this study, cortical thinning in medicated patients relative to
unmedicated patients provided preliminary evidence indicating
negative effects of mid- to long-term atypical antipsychotic
treatment on cortical thickness. Our results were consistent
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with studies showing the contribution of atypical antipsychotics
to cortical thinning in the frontal, temporal, and parietal
lobes, which has been repeatedly reported (Lesh et al., 2015;
Zhang et al., 2018; Guo et al., 2019; Liu et al., 2020), and in
the lateral orbitofrontal cortex (Gjerde et al., 2018; Akudjedu
et al., 2020). Mid- to long-term treatment effects may be
negative as a result of cumulative pharmacologic effects (Xiao
et al., 2018). A study of BD published in 2020 found that
patients currently being treated with atypical antipsychotics
had significantly reduced total gray matter volumes compared
to patients who were not taking atypical antipsychotics and
to HC, which is similar to our results (Birner et al., 2020).
The possible mechanism for cortical thinning may be that
long-term atypical antipsychotic treatment could cause some
loss of neurites, synaptic spines, or synapses in the cortical
structures (Huang and Song, 2019). Animal studies have also
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FIGURE 2 | Significant differences of cortical thickness between medicated patients and HC, and between medicated patients and unmedicated patients.
(A) Regions with significant thickness differences between medicated patients and HC. (B) Regions with significant thickness differences between medicated
patients and unmedicated patients. The significance level was set to vertex p < 0.001 with Monte Carlo cluster-wise simulation correction for cluster p < 0.01. L,
left. R, right. The color bar represents t-value. (C) Post hoc pair-wise comparisons showing thickness differences between medicated patients and HC. (D) Post hoc
pair-wise comparisons showing thickness differences between medicated patients and unmedicated patients. The significance level was set at p < 0.05 with FDR
correction for multiple comparison. ∗∗∗ p < 0.001. HC, healthy controls; R, right; L, left; SPG; superior parietal gyrus; ICG, isthmus cingulate gyrus; mSFG, medial
superior frontal gyrus; PreCG, precentral gyrus; ISN, insula; MTG, middle temporal gyrus; STG, superior temporal gyrus; ITG, inferior temporal gyrus; lOFC, lateral
orbitofrontal cortex; FFG, fusiform gyrus.

approximately 45% of the variance in thickness (Kremen et al.,
2010) but as much as 70% of the variance in surface area (Eyler
et al., 2011). These results suggest that of these two structural
measures, the brain plasticity caused by environmental influences
(atypical antipsychotics, in our study) may be mainly reflected in
changes in cortical thickness.
We observed a complex relationship between cortical
structural changes and clinical features following mid- to longterm treatment. In this study, cortical thinning was associated
with clinical improvement and, possibly, worsening cognitive
function, suggesting atypical antipsychotics have both adaptive
and maladaptive compensatory effects. Findings related to
cognitive function were not significant after FDR correction,
and further studies are needed to clarify the role of atypical
antipsychotics in cortical thinning and subsequent changes in
cognitive function. Worsening cognitive function may relate
to dopamine sensitivity in psychosis and negative prognosis
in patients receiving long-term, 7–20 years of antipsychotic
treatment (Harrow and Jobe, 2018). Prior studies have generally
indicated cortical volume loss during the course of illness
in SZ; however, there are inconsistencies in findings such as
the association of cortical structural loss with improved and
worsening clinical severity (Gur et al., 1998; Sporn et al., 2003;
Xiao et al., 2015; Walton et al., 2017; Moser et al., 2018;
Guo et al., 2019). Several studies have found that atypical
antipsychotics were associated with concurrent cortical structural

shown an association between long-term exposure to atypical
antipsychotics and reduced cortical volume (Dorph-Petersen
et al., 2005). The atypical antipsychotic medication olanzapine
was shown to exhibit neurotoxic effects by influencing autophagy
(Vucicevic et al., 2014).
Our results showed greater age-related cortical thinning in
medicated patients than in unmedicated patients and HC. The
results were consistent with those of a few studies that did
not differentiate between the effects of typical and atypical
antipsychotics (van Haren et al., 2011; Alexander-Bloch et al.,
2014) on cortical thinning and contradict the absence of
an effect of antipsychotics on the age-related trajectory of
cortical measures. We cannot deny that psychiatric disorders
are progressive brain diseases that cause changes in cortical
structures (van Haren et al., 2012). However, when illness
duration was used as a covariate, all significant regions except the
right parietal cortex survived. Moreover, we did not find evidence
of an interaction between illness duration and group. Thus, we
consider that the effect of atypical antipsychotics on thickness was
greater than the effect of the disease itself (Fusar-Poli et al., 2013;
Birner et al., 2020).
One possible reason for the occurrence of cortical thinning
but not surface area reduction is that they have different neural
mechanisms. In studies examining the role of genetic and
environmental factors in thickness and surface area in a sample
of 1,237 healthy adult twins, genetic factors contributed to
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TABLE 3 | Relationship between cortical thickness and clinical symptoms or cognitive function in all patients (medicated and unmedicated).
Regions variables

SPG.R

ICG.R

mSFG.R

ICG.L

PreCG.R

INS.R

INS.L

MTG.R

OFC.R

STG.L

ITG.L

mSFG.L

Clinical symptoms
HAMD total score

0.283/
<0.001***

0.181/0.034* 0.186/0.030* 0.210/0.014*

Somatic anxiety

0.295/
<0.001***

0.181/0.034* 0.206/0.016* 0.232/0.006**

Psychic anxiety

0.263/
0.002**

HAMD factor scores

Core depressive

0.186/0.029*

0.209/0.014*

0.204/0.017*

0.186/0.030*

0.201/0.019* 0.182/0.034* 0.172/0.045*

Anorexia
HAMA total score

0.225/0.011*

0.195/0.028* 0.185/0.037*

YMRS total score

−0.200/0.028*

BPRS total score

0.211/0.011*

BPRS factor scores
9

Anxiety and depression
Lack of energy

0.179/0.032* 0.192/0.021*
0.185/0.026*

Thought disorder

0.173/0.038*

Activity
Hostility

0.178/0.033*

0.256/0.002** 0.183/0.028* 0.267/0.001** 0.226/0.006**

0.197/0.018* 0.182/0.029* 0.224/0.007** 0.297/0.018*

Cognitive function
WCST
Correct responses

0.205/0.043* 0.253/0.012*

Categories completed

0.218/0.031* 0.227/0.025*

Total errors

−0.205/0.043* −0.253/0.012*

Non-perseverative errors

0.205/0.034*
−0.268/0.008**−0.213/0.036*
−0.218/0.032*

−0.230/0.023*

Exploratory partial correlation analyses controlling for age and sex were performed to determine the relationship between cortical thickness and clinical symptoms (HAMD total scores and its factors; HAMA total scores;
YMRS total scores; and BPRS total scores and its factors) and cognitive function (WCST scores) separately. Data were presented as r-value/uncorrected p value; ***p < 0.001, **p < 0.01, *p < 0.05. Bold indicates
significance at p < 0.05, after FDR correction. R, right; L, left; SPG; superior parietal gyrus; ICG, isthmus cingulate gyrus; mSFG, medial superior frontal gyrus; PreCG, precentral gyrus; INS, insula; MTG, middle temporal
gyrus; lOFC, lateral orbitofrontal Cortex; STG, superior temporal gyrus; ITG, inferior temporal gyrus.
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FIGURE 3 | Age-related differences in cortical thickness among healthy controls, medicated patients, and unmedicated patients. HC, healthy controls.

loss and clinical improvement (Ahmed et al., 2015; Lesh
et al., 2015; Guo et al., 2019). Further, atypical antipsychotics
may have mechanistic role in cortical thinning as well as
clinical improvement. Interestingly, greater cortical volume

Frontiers in Neuroscience | www.frontiersin.org

reduction in medicated adults and adolescents with SZ has been
associated with greater clinical improvement at 3-year followup independent of medication types or baseline or follow-up
clinical severity (Gur et al., 1998; Sporn et al., 2003). Some
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TABLE 4 | Average rate of change in cortical thickness per year for healthy controls, the medicated patients, and the unmedicated patients.
Brain region

HC (mm/year)

Medicated (mm/year)

Unmedicated (mm/year)

Medicated vs. Unmedicated

Medicated vs. HC

Inferior temporal gyrus

−0.003

−0.006

−0.003

↓

↓

Insula

−0.005

−0.008

−0.004

↓**

↓***

Superior frontal gyrus

−0.009

−0.011

−0.006

↓*

↓***

Superior temporal gyrus

−0.005

−0.006

−0.006

↑*

↓**

Isthmus cingulate gyrus

−0.007

−0.004

−0.005

↑

↑***

Middle temporal gyrus

−0.004

−0.006

−0.001

↓**

↓***

Insula

−0.006

−0.010

−0.006

↓***

↓***

Lateral orbitofrontal cortex

−0.005

−0.010

−0.006

↓*

↓***

Precentral gyrus

−0.003

−0.005

−0.001

↓

↓***

Isthmus cingulate gyrus

−0.006

−0.009

−0.003

↓*

↓***

Superior parietal cortex

−0.005

−0.004

−0.003

↓

↑**

Superior frontal gyrus

−0.008

−0.009

−0.008

↓***

↓***

Superior temporal gyrus

−0.005

−0.004

−0.007

↑

↑

Left hemisphere

Right hemisphere

HC, healthy controls; the significance level was set at p < 0.05 with FDR correction for multiple comparison. ***p < 0.001, **p < 0.01, *p < 0.05. ↓, greater agerelated thickness thinning in medicated patients compared to unmedicated patients or HC; ↑, smaller age-related thickness thinning in medicated patients compared to
unmedicated patients or HC.

were treated with more than one medication, and it was
difficult to identify patients treated with a single medication.
Therefore, it is unclear whether specific atypical antipsychotics
cause cortical structure abnormalities. There may be interactions
between different medications, a possibility that requires further
investigation. Additionally, we note that the illness duration
differed significantly between the medicated and unmedicated
groups. However, this study demonstrated no effect of illness
duration on the results. The multiple regression analysis and
lack of interaction between illness duration and thickness
argued against the possibility that our results were due to
differences in illness duration between groups. Finally, given
our cross-sectional design, the age-related results provided
only a preliminary exploration of the cortical structural
changes associated with atypical antipsychotics. However, it
has been noted that most accelerated aging studies are crosssectional designs. A longitudinal, placebo-controlled randomized
controlled trial (RCT) design would be better, but patients
in such studies would not be representative. Our real-world
observations can provide complementary information and are
more representative of the real-world situation. Second, our
sample size was moderate and had a relatively wide age range
(13–45 years). The broad age range and cross-sectional design
may have limited the interpretation of our findings. Finally, the
correlation findings are tentative because the uncorrected p and r
values were generally modest, indicating modest effects.
Our major findings suggest that mid- to long-term atypical
antipsychotic treatment is related to regional cortical thinning
but not to a reduction in surface area and is associated with
cognitive impairment. Furthermore, we provide the first evidence
of age-related differences in the effects of mid- to long-term
atypical antipsychotic treatment on cortical thickness in SZ and
BD, suggesting that mid- to long-term atypical antipsychotic
treatment may have negative effects.

data found a negative correlation between cortical volume and
regional homogeneity (ReHo) in the right inferior temporal
gyrus in drug-naïve SZ but not in HC, suggesting that cortical
volume reductions could be associated with increased ReHo
(greater brain network integration) in SZ (Hong et al., 2019).
In addition, cortical thinning has also been observed in highrisk people without disease onset (Bois et al., 2015). Altogether,
these studies suggest that cortical thinning in medicated patients
represent a potential compensatory mechanism associated with
clinical improvement. Conceivably, cortical thinning could occur
through known compensatory synaptic and cellular pruning of
malfunctioning neurons. However, atypical antipsychotics are
unlikely able to correct or arrest cortical defects and their
progression that are already present.
Interestingly, we also observed more thickness in the left
superior frontal gyrus and the inferior temporal gyrus in
unmedicated patients than in medicated patients and HC.
Greater thickness in these regions may be related to insufficient
synaptic pruning during the neurodevelopmental process in SZ
(Xiao et al., 2015). Moreover, we observed a trend of greater
cortical thickness in the forebrain and less cortical thickness
in the hindbrain in unmedicated patients than in HC. This is
in line with the low-frequency fluctuation (ALFF) and regional
homogeneity (ReHo) results of previous large-sample functional
studies conducted by our group (Wei et al., 2018; Chang et al.,
2019), suggesting that there are disease-related physiological
imbalances (such as functional imbalances) that lead to cortical
structural changes through some mechanisms. The negative
findings of disease effects on surface area may be because the
surface area is a weak intermediate phenotype for psychiatric
disorders (Neilson et al., 2019). Our sample size is not adequate
to identify disease-related differences.
There are several limitations to our study. First, the present
study was conducted in a real-world context. Most patients
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